Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval

Executive Summary

FDA should consider approving Idec's Zevalin for use in lymphoma patients who have not failed Rituxan therapy under the accelerated approval regulations, FDA's Oncologic Drugs Advisory Committee said Sept. 11.

You may also be interested in...



From Avastin To Zevalin: ODAC’s Most Memorable Moments

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January

Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17

Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January

Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17

Related Content

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel